您当前的位置：
首页 >
文章列表页 >
Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer
更新时间：2026-02-10

    • Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer

    • “From the perspective of the Chinese healthcare system, experts constructed a Markov model based on REZOR trial data to study the cost-effectiveness of remitinib compared to gefitinib in first-line treatment of EGFR mutation positive advanced NSCLC. The results showed that the remitinib regimen has an absolute economic advantage.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 1, Pages: 55-60(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.01.10    

      CLC： R956

    • Received：04 September 2025，

      Revised：2025-12-24，

      Accepted：25 December 2025，

      Published：15 January 2026

    移动端阅览

  • ZHU Xiaowei,ZHU Tongming,YI Jia,et al.Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer[J].ZHONGGUO YAOFANG,2026,37(01):55-60. DOI： 10.6039/j.issn.1001-0408.2026.01.10.

  •  
  •  

0

Views

13

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer
Cost-utility analysis of tislelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
Cost-utility analysis of multiple sequential treatment regimens for HER-2 positive advanced gastric cancer
Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib
Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

Related Author

ZHENG Ying
GAO Qian
DONG Lei
HU Dongxue
YU Fangzhu
WANG Danfeng
HU Shiyuan
LI Shunping

Related Institution

School of Pharmacy， Hebei Medical University
Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University
Dept. of Pharmacy， Hebei Children’s Hospital
Centre for Health Management and Policy Research， School of Public Health， Cheeloo College of Medicine， Shandong University
NHC Key Lab of Health Economics and Policy Research （Shandong University）
0